Top

Published in:

Open Access 01-12-2015 | Case report

From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report

Authors: Karolina Vernmark, Maria Albertsson, Bergthor Björnsson, Thomas Gasslander, Per Sandström, Xiao-Feng Sun, Annika Holmqvist

Published in: BMC Cancer | Issue 1/2015

Abstract

Background

Mucinous adenocarcinoma (MAC) represents 6-19 % of all colorectal carcinoma. It is associated with poorer response to chemotherapy and chemoradiotherapy.

Case presentation

A 27-year-old Swedish woman presented with stomach pain and weight loss, and was diagnosed with locally advanced MAC in the transverse colon as well as 3 liver metastases. Neoadjuvant treatment with fluorouracil, folinic acid and oxaliplatin (FLOX) failed due to several infections, pulmonary embolism and deteriorated performance status. The patient was therefore considered palliative. Palliative treatment with metronomic capecitabine 500 mg × 2 daily and bevacizumab every other week were initiated. After 4 months of treatment the tumors had regressed and the patient was able to undergo radical surgery, thereby changing the treatment intention from palliative to curative. No adjuvant chemotherapy was given. There were no signs of recurrence 9 months later.

Conclusions

The role of the combination of metronomic capecitabine and bevacizumab in patients with MAC merits further investigation.

Zhang H, Evertsson S, Sun X. Clinicopathological and genetic characteristics of mucinous carcinomas in the colorectum. Int J Oncol. 1999;14(6):1057–61.PubMed

Verhulst J, Ferdinande L, Demetter P, Ceelen W. Mucinous subtype as prognostic factor in colorectal cancer: a systematic review and meta-analysis. J Clin Pathol. 2012;65(5):381–8.CrossRefPubMed

Hyngstrom JR , Hu CY, Xing Y, You YN, Feig BW, Skibber JM et al. Clinicopathology and outcomes for mucinous and signet ring colorectal adenocarcinoma: analysis from the National Cancer Data Base. Ann Surg Oncol. 2012;19(9):2814–21.CrossRefPubMedPubMedCentral

Umpleby HC, Ranson DL, Williamson RC. Peculiarities of mucinous colorectal carcinoma. Br J Surg. 1985;72(9):715–8.CrossRefPubMed

Nozoe T , Anai H, Nasu S, Sugimachi K. Clinicopathological characteristics of mucinous carcinoma of the colon and rectum. J Surg Oncol. 2000;75(2):103–7.CrossRefPubMed

Akino F , Mitomi H, Nakamura T, Ohtani Y, Ichinoe M, Okayasu I. High apoptotic activity and low epithelial cell proliferation with underexpression of p21(WAF1/CIP1) and p27Kip1 of mucinous carcinomas of the colorectum: comparison with well-differentiated type. Am J Clin Pathol. 2002;117(6):908–15.CrossRefPubMed

Connelly JH, Robey-Cafferty SS, Cleary KR. Mucinous carcinomas of the colon and rectum. An analysis of 62 stage B and C lesions. Arch Pathol Lab Med. 1991;115(10):1022–5.PubMed

Halvorsen TB, Seim E. Influence of mucinous components on survival in colorectal adenocarcinomas: a multivariate analysis. J Clin Pathol. 1988;41(10):1068–72.CrossRefPubMedPubMedCentral

Messerini L , Vitelli F, De Vitis LR, Mori S, Calzolari A, Palmirotta R et al. Microsatellite instability in sporadic mucinous colorectal carcinomas: relationship to clinico-pathological variables. J Pathol. 1997;182(4):380–4.CrossRefPubMed

10.

Lupinacci RM, Mello ES, Coelho FF, Kruger JA, Perini MV, Pinheiro RS et al. Prognostic implication of mucinous histology in resected colorectal cancer liver metastases. Surgery. 2014;155(6):1062–8.CrossRefPubMed

11.

Shin US, Yu CS, Kim JH, Kim TW, Lim SB, Yoon SN et al. Mucinous rectal cancer: effectiveness of preoperative chemoradiotherapy and prognosis. Ann Surg Oncol. 2011;18(8):2232–9.CrossRefPubMed

12.

Younes M, Katikaneni PR, Lechago J. The value of the preoperative mucosal biopsy in the diagnosis of colorectal mucinous adenocarcinoma. Cancer. 1993;72(12):3588–92.CrossRefPubMed

13.

Niv Y. Mucin and colorectal cancer metastasis. Am J Gastroenterol. 1994;89(5):665–9.PubMed

14.

Maiti R. Metronomic chemotherapy. J Pharmacol Pharmacother. 2014;5(3):186–92.CrossRefPubMedPubMedCentral

15.

Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer. 2013;49(16):3387–95.CrossRefPubMed

16.

Fedele P, Marino A, Orlando L, Schiavone P, Nacci A, Sponziello F et al. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer. Eur J Cancer. 2012;48(1):24–9.CrossRefPubMed

17.

Miger J, Holmqvist A, Sun XF, Albertsson M. Low-dose capecitabine (Xeloda) for treatment for gastrointestinal cancer. Med Oncol. 2014;31(3):870.CrossRefPubMedPubMedCentral

18.

Romiti A, Onesti CE, Roberto M, Barucca V, Tomao S, D'Antonio C et al. Continuous, low-dose capecitabine for patients with recurrent colorectal cancer. Med Oncol. 2015;32(3):54.CrossRefPubMed

19.

Digklia A, Voutsadakis IA. Combinations of vascular endothelial growth factor pathway inhibitors with metronomic chemotherapy: Rational and current status. World J Exp Med. 2014;4(4):58–67.CrossRefPubMedPubMedCentral

20.

Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM et al. A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer. Br J Cancer. 2013;109(7):1725–34.CrossRefPubMedPubMedCentral

21.

Baranyai Z, Jósa V, Krzystanek M, Eklund AC, Szász AM, Szállási Z. Evaluation of thrombocytosis as predictive factor in colorectal cancer. Magy Seb. 2013;66(6):331–7.CrossRefPubMed

22.

Phipps AI, Buchanan DD, Makar KW, Win AK, Baron JA, Lindor NM et al. KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers. Br J Cancer. 2013;108(8):1757–64.CrossRefPubMedPubMedCentral

23.

Carstens H, Albertsson M. Successful treatment with low-dose capecitabine for disseminated esophageal adenocarcinoma. Acta Oncol. 2007;46(6):866–8.CrossRefPubMed

Title: From palliative to curative treatment - stage IV mucinous adenocarcinoma, successfully treated with metronomic capecitabine in combination with Bevacizumab and surgery- a case report
Authors: Karolina Vernmark
Maria Albertsson
Bergthor Björnsson
Thomas Gasslander
Per Sandström
Xiao-Feng Sun
Annika Holmqvist
Publication date: 01-12-2015
Publisher: BioMed Central
Published in: BMC Cancer / Issue 1/2015
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-015-1908-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2015

Combined comparative genomic hybridization and transcriptomic analyses of ovarian granulosa cell tumors point to novel candidate driver genes

Prevalence and outcomes of extrahepatic primary malignancy associated with Hepatocellular Carcinoma in a Korean population

STK33 overexpression in hypopharyngeal squamous cell carcinoma: possible role in tumorigenesis

Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells

TIF1γ interferes with TGFβ1/SMAD4 signaling to promote poor outcome in operable breast cancer patients

The effectiveness and safety of platinum-based pemetrexed and platinum-based gemcitabine treatment in patients with malignant pleural mesothelioma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer